Cel Sci (CVM) Interest Coverage Ratio Growth (3y) (2013 - 2026)
Cel Sci (CVM) Interest Coverage Ratio Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 29.79% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 33.30% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 78.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 81.16% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -35.50% |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.29% |
| Dec 31, 2025 | -8.56% |
| Sep 30, 2025 | 18.33% |
| Jun 30, 2025 | -4.46% |
| Mar 31, 2025 | -309.10% |
| Dec 31, 2024 | -2.88% |
| Sep 30, 2024 | -31.39% |
| Jun 30, 2024 | 88.72% |
| Mar 31, 2024 | -4.87% |
| Dec 31, 2023 | -537.58% |
| Sep 30, 2023 | -43.73% |
| Jun 30, 2023 | 82.74% |
| Mar 31, 2023 | 82.77% |
| Dec 31, 2022 | -3.15% |
| Sep 30, 2022 | 22.22% |
| Jun 30, 2022 | 71.72% |
| Mar 31, 2022 | 79.67% |
| Dec 31, 2021 | -39.50% |
| Sep 30, 2021 | -103.92% |
| Jun 30, 2021 | -84.72% |